ReviewNuclear medicine and biology2021
The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
Review in Nuclear medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- [Breast (Edinburgh, Scotland) · 2026Trial
- A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2- Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Response.Cancer research and treatment · 2025Trial
- ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer.JAMA network open · 2024Trial
- The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Macrocycle Chelator Conjugation on the C3 Hydroxyl Group of 17β-Estradiol reduces Estrogen Receptor Binding.Molecular imaging and biology · 2026Article
- Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [Cancer innovation · 2026Article
- A comprehensive review of de novo oligometastatic breast cancer: Current treatment options, surgical outcomes, and systemic therapy.Northern clinics of Istanbul · 2026Review
- Quantitative and simplified [18F] fluoroestradiol positron emission tomography (PET) measures of brain estrogen receptor expression.European journal of nuclear medicine and molecular imaging · 2026Article
- Hybrid [AJNR. American journal of neuroradiology · 2025Article
- A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer.Scientific reports · 2025Article
- The Role of [Cancers · 2025Review
- EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice.Scientific reports · 2024Article
- Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress.Diagnostics (Basel, Switzerland) · 2024Review
- Characterization of an Estrogen Receptor α-SelectiveWorld journal of nuclear medicine · 2024Article
- Estrogen Receptor-targeted PET Imaging for Breast Cancer.Radiology · 2024Review
- Radiosynthesis and Preclinical Evaluation ofCancers · 2024Article
- In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology.Scientific reports · 2024Article
- Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.International journal of molecular sciences · 2024Review
- Expression of the excitatory opsin ChRERα can be traced longitudinally in rat and nonhuman primate brains with PET imaging.Science translational medicine · 2023Article
- Invited Commentary: A Recently Approved PET Imaging Agent to Guide Breast Cancer Therapy.Radiographics : a review publication of the Radiological Society of North America, Inc · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
introduction16α-[ METHODS AND
resultsThe development of methods for efficient production of fluorine-18, for conversion of [ ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: Comparisons between ER levels measured by FES-PET imaging of breast tumors with tissue-specimen ER quantification by IHC and other methods show that imaging provided improved prediction of benefit from endocrine therapies. Serial imaging of ER by FES-PET, before and after dosing patients with antiestrogens, is used to determine the efficacious dose for established antiestrogens and to facilitate clinical development of new ER antagonists. Beyond FES imaging, PET-based hormone challenge tests, which evaluate the functional status of ER by monitoring rapid changes in tumor metabolic or transcriptional activity after a brief estrogen challenge, provide highly sensitive and selective predictions of whether or not there will be a favorable response to endocrine therapies. There is sufficient interest in the clinical applications of FES that FDA approval is being sought for its wider use in breast cancer.
conclusionsFES was the first PET probe for a receptor in cancer, and its development and clinical applications in breast cancer parallel the conceptual evolution of the whole field of receptor-binding radiotracers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.